Resmetirom reduces cardiovascular and liver risk markers in MASH patients, with 49% achieving significant liver stiffness improvement within nine...

TG Therapeutics' ublituximab meets primary endpoint in Phase 3 RMS trial, enabling single-visit initiation dosing versus competitors.

Sacituzumab tirumotecan plus pembrolizumab cuts NSCLC progression risk by 65% in OptiTROP-Lung05 trial, with median PFS not reached versus...

Zenas BioPharma files BLA for obexelimab in IgG4-Related Disease with 56% flare reduction versus placebo over 52 weeks.

Children with cancer wait 6.5 years longer than adults to access new drugs. Adaptive and tumor-agnostic designs can close...

Rezdiffra reduces cardiovascular and liver risk markers in MASH patients, with significant reductions in Lp(a) and portal hypertension probability...

Spevatamig Plus Chemotherapy shows 52.4% response rate in pancreatic cancer, more than doubling historical chemotherapy-alone outcomes in Phase 2...

Ublituximab single-infusion dosing achieves bioequivalence target in Phase 3 ENHANCE trial with lower infusion-related reaction rates than prior studies.

Apogee's zumilokibart achieves 65.9% EASI-75 response in Phase 2 atopic dermatitis trial, with fewer injections than current standards.

Zenas BioPharma submits BLA for obexelimab in IgG4-Related Disease, showing 56% flare reduction over 52 weeks with p=0.0005 across...